{{medical}}
[[File:EPR-Effekt.svg|thumb]]
'''高渗透长滞留效应'''（{{lang-en|enhanced permeability and retention effect}}，缩写'''EPR'''，或译为'''增强渗透滞留效应'''） 是指一些特定大小的大分子物质（如[[脂质体|脂质体]]、[[纳米颗粒|纳米颗粒]]以及一些大分子药物）更容易渗透进入肿瘤组织并长期滞留（和正常组织相比）的现象，1986年由日本科學家[[前田浩|前田浩]]与{{link-ja|松村保廣|松村保広}}發現<ref name="matsamura">{{Cite journal|author = Matsumura Y, Maeda H|title = A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs|journal = Cancer Research|volume = 46|issue = 12 Pt 1|pages = 6387–92|date = December 1986|pmid = 2946403|url = http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=2946403}}</ref><ref name="duncan">{{Cite journal|author = Duncan, R. and Sat Y.-N.|title = Tumour targeting by enhanced permeability and retention (EPR) effect|journal = Ann. Oncol.|volume = 9 (Suppl.2)|issue = |year = 1998|pages = 39}}</ref><ref name="vasey">{{Cite journal|vauthors = Vasey PA, Kaye SB, Morrison R, etal|title = Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee|journal = Clinical Cancer Research|volume = 5|issue = 1|pages = 83–94|date = January 1999|pmid = 9918206|url = http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=9918206}}</ref>。对此常见的解释是，肿瘤细胞为了能够快速地生长，需要更多的养料和[[氧气|氧气]]，故会分泌[[血管内皮生长因子|血管内皮生长因子]]等与肿瘤[[血管新生|血管生成]]有关的[[生长因子|生长因子]]。特别是当肿瘤达到150-200[[微米|微米]]大小时，会高度依赖于肿瘤血管的养料和氧气供应。此时新生成的肿瘤血管在结构与形态上与正常的血管有很大的不同。其[[內皮|內皮细胞]]间隙较大，缺少[[血管壁|血管壁]][[平滑肌|平滑肌]]层，[[血管紧张素|血管紧张素]]受体功能缺失。另外，肿瘤组织也缺少[[淋巴系統|淋巴管]]致使淋巴液回流受阻。这两者造成了大分子物质可以方便地穿过过血管壁在肿瘤组织中富集，且不被淋巴液回流带走而能长期存于肿瘤组织，故称为[[新生物|实体瘤]]的“高渗透长滞留效应”（EPR）。EPR效应可被一些病理生理因素进一步提高，如刺激肿瘤血管舒张的物质[[缓激肽|缓激肽]]、[[一氧化氮|一氧化氮]]、[[过氧亚硝酸根|过氧亚硝酸根]]离子、[[前列腺素|前列腺素]]、血管内皮生长因子、[[肿瘤坏死因子|肿瘤坏死因子]]等。另外，肿瘤部位的淋巴细胞减少也会增加大分子物质在这里的滞留效应。

EPR效应对[[纳米颗粒|纳米颗粒]]和[[脂质体|脂质体]]对肿瘤部位的给药相当重要<ref name="Maeda">[http://www.ncbi.nlm.nih.gov/pubmed/22595146] {{Wayback|url=http://www.ncbi.nlm.nih.gov/pubmed/22595146 |date=20150803192721 }}, Maeda H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond.</ref>。许多工作利用了金[[纳米颗粒|纳米颗粒]]的热[[燒蝕|燒蝕]]作用，金[[纳米颗粒|纳米颗粒]]通过这一效应在肿瘤部位富集后，被[[生物组织光学窗口|可穿透皮肤的]][[近红外|近红外]][[激光|激光]]的[[光热效应|光热效应]]加热而产生高温，以此来杀死肿瘤。这一方法也可与[[化学疗法|化学疗法]]等其它疗法联用来取得更好的效果<ref>{{Cite journal|author = Poon RT, Borys N|title = Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer|journal = Expert Opinion on Pharmacotherapy|volume = 10|issue = 2|pages = 333–43|date = February 2009|pmid = 19236203|doi = 10.1517/14656560802677874}}</ref> 。

虽然在动物实验上效果良好，但在人体模型上效果并不突出<ref>{{Cite journal|author = Danhier F|title = To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?|journal = J Control Release|volume = 244|issue = Pt A|pages = 108-121|date =2016-12-28|pmid = 27871992|doi = 10.1016/j.jconrel.2016.11.015}}</ref> 。

== 参考文献 ==
{{Reflist}}
[[Category:肿瘤学|Category:肿瘤学]]